Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …

Prostate cancer is the most commonly diagnosed cancer affecting men in the United States.
The prostate is a hormone-dependent gland in which androgen hormones testosterone and …

Hypercholesterolemia and dyslipidemia are associated with an increased risk for many
cancer types and with poor outcomes in patients with established disease. Whereas the …

Androgen receptor (AR) is a steroid receptor transcriptional factor for testosterone and
dihydrotestosterone consisting of four main domains, the N-terminal domain, DNA-binding …

During the past 10 years, preclinical studies implicating sustained androgen receptor (AR)
signalling as the primary driver of castration-resistant prostate cancer (CRPC) have led to …

Around 80–90% of prostate cancer (PCa) cases are dependent on androgens at initial
diagnosis; hence, androgen ablation therapy directed toward a reduction in serum …

Despite advances in prostate cancer diagnosis and management, morbidity from prostate
cancer remains high. Approximately 20% of men present with advanced or metastatic …

Continued androgen receptor (AR) signaling is an established mechanism underlying
castration-resistant prostate cancer (CRPC), and suppression of androgen receptor …

Abstract In the United States, prostate cancer (PCa) is the most commonly diagnosed non-
cutaneous cancer in males and the second leading cause of cancer-related death for men …

The discovery of corticotropin-releasing factor (CRF) or CRH defining the upper regulatory
arm of the hypothalamic-pituitary-adrenal (HPA) axis, along with the identification of the …